This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.63% per year. These returns cover a period from January 1, 1988 through December 2, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO faces slowing Wegovy and Ozempic momentum, pricing risks and fierce competition ahead of Q3 earnings.
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil
by Zacks Equity Research
VKTX posts a wider Q3 loss and no sales, as R&D costs surge and obesity drug studies drive spending higher.
Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?
by Ahan Chakraborty
Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded drug headwinds.
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $33.54, denoting a -3.44% move from the preceding trading day.
Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have?
by Sundeep Ganoria
VKTX is likely to have headed into Q3 earnings with no product revenue, pipeline updates in focus and widening loss forecasts testing investor patience.
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking Therapeutics
by Zacks Equity Research
Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 results.
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio
by Zacks Equity Research
Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.
How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?
by Sundeep Ganoria
Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) closed at $33.05 in the latest trading session, marking a -2.54% move from the prior day.
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?
by Ahan Chakraborty
NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.
Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?
by Ahan Chakraborty
NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $32.37, indicating a +2.65% shift from the previous trading day.
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $27.88, denoting a +1.86% move from the preceding trading day.
Can NVO Maintain Obesity Leadership With Next-Generation Candidates?
by Ahan Chakraborty
Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $25.09, indicating a -5.78% shift from the previous trading day.
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?
by Sundeep Ganoria
VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.
LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?
by Kinjel Shah
Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity drug battle.
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $24.97, denoting a -4.88% move from the preceding trading day.
Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?
by Zacks Equity Research
NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for added benefits.
LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?
by Zacks Equity Research
Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.
NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity
by Zacks Equity Research
Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
by Sundeep Ganoria
Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.